DRC receives 70,000 Ebola vaccine doses amid worsening Bundibugyo outbreak

The Democratic Republic of the Congo (DRC) has received an initial shipment of 70,000 doses of the Ervebo Ebola vaccine to bolster efforts against the escalating Bundibugyo virus disease outbreak. This allocation, announced by the World Health Organization (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC), follows a request from the DRC government for access to the global vaccine stockpile.

Of the 70,000 doses, a significant portion, 20,000, will be dedicated to a Phase III clinical trial. This trial aims to determine if the Ervebo vaccine, primarily licensed for the Zaire species of Ebola virus, can provide protection against the Bundibugyo virus. The remaining 50,000 doses are designated for frontline healthcare workers, adhering to recommendations from the WHO Strategic Advisory Group of Experts on Immunisation (SAGE).

The decision to test Ervebo against the Bundibugyo virus stems from uncertainty about its efficacy against this specific species. While preliminary laboratory and animal studies suggest potential protection, the Phase III trial is crucial for generating definitive evidence. This research will guide future decisions on using Ervebo in similar outbreaks. Participants in the trial and those receiving the vaccine outside of it must be fully informed of the potential risks, benefits, and limitations.

The outbreak, declared on May 15, has intensified significantly, spreading across 54 health zones in six provinces: Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo, and Bas-Uélé. As of August 12, the WHO reported 4,665 confirmed cases and 2,184 deaths. The WHO characterizes the situation as intense transmission, marking it as the largest Ebola outbreak ever recorded in the DRC. Factors contributing to its spread include population movement, insecurity, artisanal mining, and cross-border travel with Uganda and South Sudan.

This widespread outbreak places immense pressure on health authorities and researchers to deploy existing interventions while simultaneously developing tools specifically tailored for the Bundibugyo virus. The situation highlights the ongoing challenges in controlling infectious diseases in complex environments.